

Prostatype Genomics AB agrees on additional top-down underwriting prior to previously announced preferential rights issue of units

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

On 15 April 2025, Prostatype Genomics AB ("Prostatype Genomics" or the "Company") announced that the Board of Directors had, subject to approval by the annual general meeting on 15 May 2025, resolved to carry out an issue of units of approximately SEK 27.3 million with preferential rights for the Company's existing shareholders (the "Rights Issue"). The Company has now agreed on an additional top-down underwriting of SEK 3 million, corresponding to approximately eleven percent of the issue proceeds. The rights issue is thus covered by pre-subscription and underwriting commitments totalling approximately SEK 22.1 million, corresponding to a total of approximately 81 percent. For the additional top-down underwriting commitment that has been agreed, compensation is paid in the form of units of 16 percent of the guaranteed amount. No cash compensation is paid.

Pre-subscription and underwriting commitments

With the newly agreed second top-down underwriting tranche, the Rights Issue is now secured in writing to in total approximately 81 percent through pre-subscription and underwriting commitments, where members of the Board as well as other existing shareholders, have provided pre-subscription commitments of a total amount of approximately SEK 3.4 million, corresponding to approximately 12.6 percent of the Rights Issue, a large shareholder has provided a compensation-free top-down underwriting commitment (from 100 percent down to approximately 85.5 percent) of approximately SEK 4 million, corresponding to approximately 14.5 percent of the Rights Issue, an external underwriter has provided a top-down underwriting commitment (from approximately 85.5 percent down to approximately 74.5 percent) of approximately SEK 3 million, corresponding to approximately 11 percent of the Rights Issue and three other external underwriters have provided bottom underwriting commitments totalling approximately SEK 11.7 million, corresponding to approximately 42.9 percent of the Rights Issue and stemming from the pre-subscribed level of 12.6 percent, up to approximately 55.5 percent of the Rights Issue.

Indicative time plan for the Rights Issue

- 15 May 2025: Annual General Meeting to, among other things, resolve on approving the Board's resolution on the Rights Issue
- 15 May 2025: Last day of trading in the share including the right to receive unit rights
- 16 May 2025: First day of trading in the share excluding the right to receive unit rights
- 19 May 2025: Record date
- 21-30 May 2025: Trading in unit rights

- 21 May 2025-4 June 2025: Subscription period
- 21 May 2025 - until approximately one week after the Rights Issue has been registered with the
- Swedish Company Registration Office (sw. Bolagsverket): Trading in BTU
- 5 June 2025: Announcement of press release with outcome of Rights Issue

Advisors

Prostatype Genomics has mandated Navia Corporate Finance AB and Gemstone Capital A/S as financial advisors, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as settlement agent in connection with the Rights Issue.

For more information about the Rights Issue, please contact:

Navia Corporate Finance AB

E-mail: info@naviacf.se

Website: www.naviacorporatefinance.com

or

Gemstone Capital ApS

E-mail: info@gemstonecapital.com

Website: www.gemstonecapital.com

For more information about the Company, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser

Carnegie Investment Bank AB (publ)

Telephone: +46 (0)73 856 42 65

E-mail: certifiedadviser@carnegie.se

About Prostatype Genomics

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB. The Company's Certified Adviser is Carnegie Investment Bank AB.

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Prostatype Genomics. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics takes place solely through the prospectus that Prostatype Genomics intends to publish around 15 May 2025.

The information contained in this press release may not be disclosed, published or distributed, directly or indirectly, within or to the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction where such action would be illegal, subject to legal restrictions or require measures other than those that follow from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. No shares or other securities of Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933 from time to time ("Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and pursuant to the securities laws of the relevant state or other jurisdiction in the United States. This communication is distributed to and directed solely to persons in the United Kingdom who are (i) professional investors falling within the scope of Article 19(5) of the U.K. from time to time in force; Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("the Order") or (ii) high net worth subjects and other persons to whom this notice may lawfully be addressed, who are subject to Article 49(2)(a)-(d) in the Order (all such persons are collectively referred to as "Relevant Persons"). Persons who are not Relevant Persons may not act on or rely on the information in this communication. An investment or investment measure referred to in this communication is only possible for Relevant Persons and will only be completed with Relevant Persons. Persons who disseminate this communication must themselves ensure that such dissemination is permitted.

Forward-looking Statements

This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should" "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements.

Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Nasdaq First North Growth Markets' regulations for issuers.

